Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EORTC CLTF 2021 | Lacutamab for CTCL

Rudolf Stadler, MD, PhD, University Medical Center Minden, Minden, Germany, shares an overview of novel therapies which are currently under investigation for the treatment of cutaneous T-cell lymphoma (CTCL), highlighting the antibody therapy lacutamab which has demonstrated promising early results in the treatment of Sézary syndrome and mycosis fungoides. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.